Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01530659 |
Recruitment Status :
Completed
First Posted : February 10, 2012
Last Update Posted : April 15, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Retinitis Pigmentosa Usher Syndrome Type 2 Usher Syndrome Type 3 | Drug: NT-501 Procedure: Sham | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 22 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | May 31, 2021 |
Actual Study Completion Date : | May 31, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: NT-501
Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
|
Drug: NT-501
Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
Other Name: CNTF, Encapsulated Cell Therapy, ECT |
Sham Comparator: Sham
Sham surgery
|
Procedure: Sham
Non-penetrating sham procedure to mimic implant procedure in the other eye. |
- Cone photoreceptor preservation [ Time Frame: 6, 12, 18, 24 and 30 months post implant ]Evaluation of the changes (if present)in cone photoreceptor preservation in the CNTF-treated eye vs. the sham eye as measured by AOSLO.
- Safety of the implanted NT-501 investigational product [ Time Frame: 6, 12, 18, 24, 30 and 36 months post implant ]Safety will be measured,in part, by the presence or absence of rejection or extrusion of the implanted NT-501 device.
- Change(s) in ocular function [ Time Frame: 6, 12, 18, 24, 30 and 36 months post implant ]
Change(s) in visual acuity and change in perimetry assessed by:
- Mean, median and distribution of change in best corrected visual acuity (BCVA)
- Changes in visual field using perimetry,
- Changes in the outer nuclear layer thickness as measure by sdOCT,
- Changes in full-field electroretinography (ERG) from Baseline to 12 and 24-months post implant
- The presence of peri-implant fibrosis that blocks the visual axis or affects the lens or retina
- Adverse events affecting ocular function which are thought to be potentially related to the implant
- Local or Systemic Toxicity [ Time Frame: 6, 12, 18, 24, 30 and 36 months post implant ]Local or systemic toxicities considered serious adverse events that are potentially related to the implant

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant must be between 18 and 55 years of age.
- Participant must have a diagnosis of retinitis pigmentosa or Usher Syndrome type 2 or 3 (without profound deafness or cochlear implants).
- Participant must understand and sign the protocol informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
- Best-corrected visual acuity must be no worse than 20/63 (at least 59 letters).
- Participants must have clear natural lenses.
- Participants must have less than 6 diopters myopia.
- Participants must be medically able to undergo ophthalmic surgery for the NT-501 device insertion and able to undergo all assessments and tests associated with the protocol.
- Females of childbearing potential (women with last menses <1 year prior to screening) must agree to use an effective form of birth control from study onset until they complete the study.
- Participants must have reproducible baseline AOSLO image at 2 baseline imaging sessions with quality suitable to identify a minimum of 7 regions of interest (ROIs) at which reliable cone spacing and/or density measures can be made over the central 5.7 degrees.
- Participants must have interocular symmetry of disease severity as measured by cone spacing, with a difference of less than 2 standard deviations in average cone spacing z-scores at the selected ROIs between the 2 eyes.
- Participant's clinical diagnosis must be consistent with retinal degeneration in the set of retinitis pigmentosa (RP) dystrophies.
Exclusion Criteria:
- Participant is medically unable to comply with study procedures or follow-up visits.
- Participant who has any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 3, or a nuclear opacity > standard 3 as measured on the AREDS clinical lens grading system; or participant is pseudophakic or aphakic.
- Participant has history of corneal opacification or lack of optical clarity.
- Participant has undergone LASIK surgery or other refractive surgery for either eye.
- Participant has nystagmus.
- Participant has greater than 6 diopters myopia.
- Participant has cystoid macular edema with cysts present within 4 degrees of the foveal center that prevent acquisition of at least 7 regions of interest with clear images of cone photoreceptors.
- Participant has fewer than 7 regions of interest (ROIs) present on 2 baseline AOSLO image montages.
- Participant has retinal vascular disease such as diabetic retinopathy or prior retinal vascular occlusive disease.
- Participant has chronic requirement (e.g., ≥4 weeks at a time) for ocular medications or has disease(s) that in the judgment of the examining physician are vision threatening, toxic to the lens, retina, or optic nerve or may affect the primary outcome.
- Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.
- Participant is receiving systemic steroids or other immunosuppressive medications.
- Participant is currently participating in or has participated in any other clinical trial of a drug by ocular or systemic administration within the last 6 months.
- Participant has previous exposure to an intra-ocular device or implant into the eye (excluding intra-ocular lens).
- Participant has uveitis or other retinal inflammatory disease.
- Participant has a history of myocardial infarction within the last 12 months.
- Participant is pregnant or lactating.
- Participant is considered immunodeficient or has a known history of HIV. A laboratory test for HIV will be performed, and a positive result is also an exclusion criterion.
- Participant with a history of ocular herpes zoster.
- Participant is on chemotherapy.
- Participant has a history of malignancy, except study participant with cancer treated successfully ≥5 years prior to inclusion in the trial.
- Participant with severe hearing disabilities in both ears.
- Participant who has been diagnosed and treated for amblyopia as an infant.
- Participant who, in the opinion of the study doctor, will not be a good study subject.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01530659
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Jacque Duncan, MD | University of California, San Francisco |
Responsible Party: | Neurotech Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01530659 |
Other Study ID Numbers: |
AOSLO-CNTF-FFB-01 FD-R-004100-01A1 ( Other Grant/Funding Number: FDA OOPD ) |
First Posted: | February 10, 2012 Key Record Dates |
Last Update Posted: | April 15, 2022 |
Last Verified: | April 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Retinitis pigmentosa Usher syndrome type 2 Usher syndrome type 3 |
Cone photoreceptor Vision Blind |
Usher Syndromes Retinitis Retinitis Pigmentosa Syndrome Disease Pathologic Processes Retinal Diseases Eye Diseases Eye Diseases, Hereditary Retinal Dystrophies Retinal Degeneration Genetic Diseases, Inborn Deaf-Blind Disorders |
Deafness Hearing Loss Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases Hearing Loss, Sensorineural Sensation Disorders Neurologic Manifestations Nervous System Diseases Blindness Vision Disorders Abnormalities, Multiple Congenital Abnormalities |